Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 16 articles:
HTML format
Text format



Single Articles


    August 2017
  1. MENDIVIL AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, et al
    Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience.
    Cancer Chemother Pharmacol. 2017;80:405-410.
    PubMed     Text format     Abstract available


    June 2017
  2. SHOJI T, Takatori E, Omi H, Kagabu M, et al
    A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Cancer Chemother Pharmacol. 2017 Jun 27. doi: 10.1007/s00280-017-3363.
    PubMed     Text format     Abstract available


    May 2017
  3. WANG YY, Chen YK, Hu SC, Hsu YL, et al
    CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo through oxidative stress-induced DNA damage and cell apoptosis.
    Cancer Chemother Pharmacol. 2017 May 12. doi: 10.1007/s00280-017-3330.
    PubMed     Text format     Abstract available


    March 2017
  4. MITTAPALLI RK, Nuthalapati S, Shepherd SP, Xiong H, et al
    Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    Cancer Chemother Pharmacol. 2017;79:587-594.
    PubMed     Text format     Abstract available


    February 2017
  5. ZHANG J, Liu J, Xu X, Li L, et al
    Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer.
    Cancer Chemother Pharmacol. 2017 Feb 8. doi: 10.1007/s00280-017-3238.
    PubMed     Text format     Abstract available


    February 2016
  6. ZHANG L, Cao X, Zhang L, Zhang X, et al
    UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  7. MARTINKOVA J, Blaha M, Kubecek O, Malakova J, et al
    Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Cancer Chemother Pharmacol. 2016;77:429-37.
    PubMed     Text format     Abstract available


    January 2016
  8. GIOVINAZZO H, Kumar P, Sheikh A, Brooks KM, et al
    Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    November 2015
  9. LIU P, Wang Y, Tong L, Xu Y, et al
    Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  10. AJGAL Z, Chapuis N, Emile G, Cessot A, et al
    Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
    Cancer Chemother Pharmacol. 2015;76:1033-9.
    PubMed     Text format     Abstract available


  11. MORGAN RJ, Synold TW, Longmate JA, Quinn DI, et al
    Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Cancer Chemother Pharmacol. 2015;76:897-907.
    PubMed     Text format     Abstract available


    October 2015
  12. WEI L, Ying L, Chunxia Y
    Erratum to: Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format    


    August 2015
  13. MATULONIS U, Berlin S, Lee H, Whalen C, et al
    Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
    Cancer Chemother Pharmacol. 2015;76:417-23.
    PubMed     Text format     Abstract available


    July 2015
  14. YING L, Chunxia Y, Wei L
    Inhibition of ovarian cancer cell growth by a novel TAK1 inhibitor LYTAK1.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  15. SILVA JL, Paulino E, Dias MF, Melo AC, et al
    Endometrial cancer: redefining the molecular-targeted approach.
    Cancer Chemother Pharmacol. 2015;76:1-11.
    PubMed     Text format     Abstract available


    April 2015
  16. CHEN J, Solomides C, Parekh H, Simpkins F, et al
    Cisplatin resistance in human cervical, ovarian and lung cancer cells.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: